SRRK Stock Forecast & Price Target

Scholar Rock Holding is attractive because its FDA-approved ISEMBYLD now has a broader-than-expected SMA label across subtypes and ambulatory status, opening access to nearly all of the roughly 6,600 U.S. SMA patients currently on an SMN2-targeting therapy. The positive Phase 3 SAPPHIRE data, including a 2.2-point HFMSE improvement versus placebo, and 98% retention into ONYX support meaningful efficacy, durability, and reduced physician hesitation. With management already engaging about 140 treatment centers and 2,600 prescribing physicians, plus higher net pricing assumptions of about $310k per patient per year, the company has a credible path to blockbuster sales and longer-term upside from apitegromab beyond SMA and SRK-439.

Scholar Rock Holding is a clinical-stage biopharmaceutical company whose value depends heavily on a narrow pipeline, making any setback in apitegromab, its subcutaneous formulation, or SRK-439 especially damaging to fundamentals. The excerpt highlights material payer-duration risk, with insurers potentially treating Isembyld differently from SMN modifiers because it does not preserve motor neurons, which could limit reimbursement, adoption, and long-term commercial durability even after approval. It also faces meaningful clinical, regulatory, competitive, and financial risk, including possible safety issues, a negative EC decision for European sales, pricing reform pressure, and the need for additional equity financing, while the passage notes that recent approval lifted the PoS from 95% to 100% and FY34 GAAP EPS is modeled at $6.44.